Sergey V. Nedogoda
Quick facts
Marketed products
- perindopril + moxonidine · Cardiovascular
Perindopril inhibits ACE to reduce angiotensin II formation, while moxonidine activates central imidazoline receptors to reduce sympathetic outflow, together lowering blood pressure through complementary pathways.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: